It looks as though Sage 217 is intended for use in short periods of a few weeks at a time. It will have to be confirmed if it’s safe for long term use:
“Jonas, M.D., chief executive officer of Sage. “In this development program, we are exploring the potential for patients with MDD to feel well within days, with just a 2-week course of treatment – similar to how antibiotics are used today – instead of enduring long-term chronic treatment. We believe a medicine with rapid onset and robust response could be truly paradigm shifting. SAGE-217, if successfully developed and approved, may rewrite the textbook on how the tens of millions of people suffering from MDD are treated, ultimately turning depression into a disorder, not an identity.”
Sawproblemo wrote a really good post on the Solve PFS forum. He isn’t a member here and said it was ok to post this:
"The more I read about this drug, the more I realize how this can be a real game changer for us. Sage 217 has the potential to directly help with depression, insomnia (they are dabbling with testing in this area and 217 has been shown to increase deep sleep duration in early trials), and even possibly help with some sexual sides, including libido. Here is something I found on allopregnanolone/GABA and male sexual functioning which I’m sure is common knowledge on these forums at this point but worth repeating:
"Male Sexual Behavior—
Neurosteroids may also influence male sexual behavior through GABAA receptors. Allopregnanolone has been shown in male rats to potentiate GABAA channel activity in neurons in the medial POA, a region that also produces neurosteroids and is essential for sexual interest, erection, copulation, and ejaculation (Haage and Johansson, 1999; Uchida et al, 2002; Haage et al, 2005). Pregnenolone sulfate opposes the effects of allopregnanolone."